Talazoparib
- Generic Name
- Talazoparib
- Brand Names
- Talzenna
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14F2N6O
- CAS Number
- 1207456-01-6
- Unique Ingredient Identifier
- 9QHX048FRV
- Background
Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.
...
- Indication
Talazoparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. This indication is approved by the FDA, EMA, and Health Canada.
...
- Associated Conditions
- HRR gene-mutated (HRRm) metastatic castration-resistant prostate cancer (mCRPC), Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
- Associated Therapies
- -
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- Conditions
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Jennifer Lauren Kamens
- Target Recruit Count
- 34
- Registration Number
- NCT05101551
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
Strata PATH™ (Precision Indications for Approved Therapies)
- Conditions
- Interventions
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Strata Oncology
- Target Recruit Count
- 700
- Registration Number
- NCT05097599
- Locations
- 🇺🇸
Kettering Health Network, Kettering, Ohio, United States
🇺🇸Florida Cancer Specialists - Panhandle, Tallahassee, Florida, United States
🇺🇸Florida Cancer Specialists - North, Saint Petersburg, Florida, United States
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Haider Mahdi
- Target Recruit Count
- 33
- Registration Number
- NCT05071937
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
- Conditions
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 67
- Registration Number
- NCT05059522
- Locations
- 🇺🇸
Highlands Oncology Group, PA, Springdale, Arkansas, United States
🇷🇺Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary", Omsk, Omskaya Oblast', Russian Federation
🇺🇸MSK Monmouth, Middletown, New Jersey, United States
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 24
- Registration Number
- NCT05053854
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 63
- Registration Number
- NCT05035745
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Artios Pharma Ltd
- Target Recruit Count
- 390
- Registration Number
- NCT04991480
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists, Orlando, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT04987931
- Locations
- 🇺🇸
Pfizer Inc, New York, New York, United States
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Conditions
- Recurrent Solid TumorRecurrent Ewing SarcomaRecurrent HepatoblastomaRecurrent NeuroblastomaRecurrent Malignant Germ Cell TumorRecurrent Peripheral Primitive Neuroectodermal TumorRefractory Malignant Germ Cell TumorRefractory Malignant Solid NeoplasmRefractory Peripheral Primitive Neuroectodermal TumorRecurrent Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT04901702
- Locations
- 🇺🇸
Lucille Packard Children's Hospital Stanford, Palo Alto, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Children's Healthcare of Atlanta/Emory University School of Medicine, Atlanta, Georgia, United States
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Bryan Schneider, MD
- Target Recruit Count
- 197
- Registration Number
- NCT04849364
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Georgetown University, Washington, District of Columbia, United States
🇺🇸Memorial Healthcare System, Hollywood, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.